|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:annual_report
|
2022 Annual Report
|
|
gptkbp:awards
|
Best Biotech Company 2021
|
|
gptkbp:ceo
|
gptkb:Jane_Smith
|
|
gptkbp:clinical_trial
|
Phase 1 Trials for Drug A
Phase 2 Trials for Drug B
|
|
gptkbp:collaborations
|
Collaboration with ABC Research Institute
Collaboration with XYZ Pharma
|
|
gptkbp:employees
|
gptkb:500
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:founder
|
gptkb:John_Doe
|
|
gptkbp:headquarters
|
gptkb:San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DEF Biotech
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:invention
|
Patent for Cancer Treatment Method
Patent for Gene Editing Technology
|
|
gptkbp:investment
|
gptkb:Venture_Capital_Firm_B
Venture Capital Firm A
|
|
gptkbp:key_people
|
Chief Financial Officer -Mr. Robert Brown
Chief Marketing Officer -Mr. David Black
Chief Operating Officer -Ms. Sarah Green
Chief Scientific Officer -Dr. Emily White
Chief Technology Officer -Dr. Alice Blue
|
|
gptkbp:location
|
gptkb:Europe
gptkb:North_America
|
|
gptkbp:market_cap
|
1 billion USD
|
|
gptkbp:mission
|
To improve patient outcomes through innovative therapies.
|
|
gptkbp:partnerships
|
gptkb:University_of_California
gptkb:National_Institutes_of_Health
|
|
gptkbp:products
|
gptkb:Gene_Therapy
Monoclonal Antibodies
|
|
gptkbp:research_focus
|
gptkb:cancer_treatment
Genetic Disorders
|
|
gptkbp:revenue
|
100 million USD
|
|
gptkbp:services
|
gptkb:Research_and_Development
gptkb:Clinical_Trials
|
|
gptkbp:social_responsibility
|
Sustainability Practices
Community Health Initiatives
|
|
gptkbp:stock_symbol
|
DEF
|
|
gptkbp:subsidiaries
|
DEF Diagnostics
DEF Gene Therapy
|
|
gptkbp:trademark
|
DEF Biotech Logo
DEF Gene Therapy Brand
|
|
gptkbp:values
|
gptkb:Innovation
gptkb:collaboration
Integrity
Excellence
|
|
gptkbp:vision
|
To be a leader in biotechnology solutions.
|
|
gptkbp:website
|
www.defbiotech.com
|
|
gptkbp:bfsParent
|
gptkb:WPC-1129
|
|
gptkbp:bfsLayer
|
8
|